Stratification of FH patients, via fibroblast culture or pharmacogenetic testing (which many candidates may have underwent as part of FH diagnosis), may allow personalised prediction of responsiveness to PCSK9 inhibition. Here, PCSK9 is linked to familial hyperaldosteronism.